Ryan Zeidan, Ph.D.
Dr. Zeidan’s in-depth industry knowledge spans a number of therapeutic areas and modalities. Most recently at Celgene, he oversaw the development of two late-stage oncology assets in a variety of tumor types, including advancing both assets to Phase 3 registration studies. Prior to Celgene, Dr. Zeidan was executive director, global strategy and operations, at Novartis Oncology, where he supported the company in business critical activities, including developing the five-year strategic plan and investor relations matters. Dr. Zeidan also worked at the Boston Consulting Group, where he focused on pharmaceutical and biotech strategy, and at Calando Pharmaceuticals, a biotech startup, where he was one of the key scientific contributors.
Dr. Zeidan holds a Ph.D. in chemistry and chemical engineering from the California Institute of Technology, and bachelor’s degrees in chemistry and chemical engineering from the Massachusetts Institute of Technology.